

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)  
(National Phase of International App.: PCT/US97/02219)

In re the application of: **Jochen G. SALFELD et al.**

International Application No.: **PCT/US97/02219**

International Filing Date: **10 February 1997**

U.S. Serial No.: **Not yet assigned**

Filed: **Herewith**

For: **Human Antibodies that Bind Human TNF $\alpha$**

Attorney Docket No.: **BBI-043CPUS**

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the above-identified application as follows.

In the Claims:

Please cancel claims 61-73 and 75-77.

Please amend claims 45, 47 and 48, as follows:

45. (Amended) A pharmaceutical composition comprising the antibody, or antigen-binding portion thereof, of [any of claims] claim 1[-24], and a pharmaceutically acceptable carrier.

47. (Amended) A method for inhibiting human TNF $\alpha$  activity comprising contacting human TNF $\alpha$  with the antibody, or antigen-binding portion thereof, of [any of claims] claim 1[-24] such that human TNF $\alpha$  activity is inhibited.